Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$102.50 USD

102.50
9,365,005

-2.33 (-2.22%)

Updated Oct 31, 2024 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK

by Kinjel Shah

Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.

What's in the Cards for Medtronic (MDT) in Q1 Earnings?

by Zacks Equity Research

Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.

Zacks Market Edge Highlights: Merck, PepsiCo, Honeywell, Microsoft and PNC Financial

by Zacks Equity Research

Merck, PepsiCo, Honeywell, Microsoft and PNC Financial have been highlighted in this Market Edge article.

Tracey Ryniec headshot

The Story of the Greatest Mom and Pop Investor Ever

by Tracey Ryniec

Anne Scheiber grew $5,000 into $22 million over 50 years. How'd she do it?

Merck (MRK) Enters Into Circular RNA Collaboration With Orna

by Zacks Equity Research

Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.

Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids

by Zacks Equity Research

With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Here's Why You Should Retain Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.

AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag

by Zacks Equity Research

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.

Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DJD

Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View

by Zacks Equity Research

Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth

by Zacks Equity Research

bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.

National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut

by Zacks Equity Research

National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023

by Zacks Equity Research

J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.

STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays

by Zacks Equity Research

Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

by Zacks Equity Research

Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth

by Zacks Equity Research

Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.

SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut

by Zacks Equity Research

SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.

Sheraz Mian headshot

Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's

by Sheraz Mian

Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

by Zacks Equity Research

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.